Compare Invesco Ltd. (IVZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Mesoblast Limited — how do they compare? Invesco Ltd. trades at $29.68 (market cap $13.15B), while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Invesco Ltd. is far larger — about 6.1× Mesoblast Limited's market cap, and Invesco Ltd. pays a 2.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| IVZ | MESO | |
|---|---|---|
Market Cap | $13.15B | $2.17B |
Sector | Financials | Technology |
52-Week High | $30.30 | $20.96 |
52-Week Low | $20.20 | $12.88 |
Enterprise Value | $23.39B | $2.17B |
Dividend Yield | 2.9% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
